Sol-Gel Technologies Collaboration Partner Filed First-to-File Paragraph IV Certification for Duobrii®
03 sept. 2020 07h05 HE
|
Sol-Gel Technologies Ltd.
Patent challenge initiated by Bausch Health Companies NESS ZIONA, Israel, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused...
Sol-Gel Technologies Reports Second Quarter 2020 Financial Results and Corporate Update
06 août 2020 07h08 HE
|
Sol-Gel Technologies Ltd.
New Drug Application for Epsolay® Submitted; Twyneo® New Drug Application on track for 2H 2020Top-line generic product revenue of $1.1 million in 2Q 2020Launch of additional generic product expected...
Sol-Gel Technologies to Report Second Quarter 2020 Financial Results on August 6, 2020
29 juil. 2020 07h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, July 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Partnered Generic Product Expected to Launch in the Second Quarter of 2021
28 juil. 2020 07h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, July 28, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded...
Sol-Gel Technologies Announces Agreements with Perrigo Company for Three New Generic Product Candidates
29 juin 2020 07h00 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, June 29, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded...
Sol-Gel to Present at Virtual BMO 2020 Prescriptions for Success Healthcare Conference
16 juin 2020 16h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, June 16, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel to Present at Upcoming Healthcare Investor Conferences
27 mai 2020 09h00 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, May 27, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Reports First Quarter 2020 Financial Results and Corporate Update
14 mai 2020 07h05 HE
|
Sol-Gel Technologies Ltd.
New Drug Applications for Epsolay® and Twyneo® remain on track for the second quarter and second half 2020, respectivelyCompleted a $23 million underwritten public offering in February with an...
Sol-Gel Technologies to Report First Quarter 2020 Financial Results and Company Updates on May 14, 2020
07 mai 2020 16h05 HE
|
Sol-Gel Technologies Ltd.
NESS ZIONA, Israel, May 07, 2020 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) (“Sol-Gel” or the “Company”), a clinical-stage dermatology company focused on identifying, developing...
Sol-Gel Technologies Announces Closing of Additional $5.0 Million Investment
13 avr. 2020 07h05 HE
|
Sol-Gel Technologies Ltd.
Investment is for ordinary shares and warrants to purchase ordinary shares at a combined price of $11 per ordinary share and accompanying warrants to purchase 0.80 of an ordinary share Investment...